Bypass of senescenoe after disruption of p21(CIP1)/(WAF1) gene in normal diploid human fibroblasts

Science

Volumn 277, Issue 5327, 1997, Pages 831-834

  Brown, Jeremy P ^a,b   Wei, Wenyi ^a   Sedivy, John M ^a  

^a BROWN UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P21; ASPARTATE CARBAMOYLTRANSFERASE; CAD TRIFUNCTIONAL ENZYME; CARBAMOYL PHOSPHATE SYNTHASE (GLUTAMINE HYDROLYSING); CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DIHYDROOROTASE; MULTIENZYME COMPLEX;

ARTICLE; CELL CYCLE; CHROMOSOME REPLICATION; DIPLOIDY; DNA DAMAGE; FIBROBLAST; GENE DISRUPTION; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SENESCENCE; APOPTOSIS; CELL AGING; CELL CULTURE; CELL CYCLE G1 PHASE; CELL DIVISION; ELECTROPORATION; GENE DELETION; GENE VECTOR; GENETICS; PHYSIOLOGY; TELOMERE;

APOPTOSIS; ASPARTATE CARBAMOYLTRANSFERASE; CARBAMOYL-PHOSPHATE SYNTHASE (GLUTAMINE-HYDROLYZING); CELL AGING; CELL DIVISION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DIHYDROOROTASE; DNA DAMAGE; ELECTROPORATION; FIBROBLASTS; G1 PHASE; GENE DELETION; GENE TARGETING; GENETIC VECTORS; HUMANS; MULTIENZYME COMPLEXES; TELOMERE;

EID: 0030609861     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.277.5327.831     Document Type: Article

References (41)

1. L. Hayflick and P. S. Moorhead, Exp. Cell Res. 25, 585 (1961); L. Hayflick, ibid. 37, 614 (1965); J. Campisi, G. Dimri, E. Hara, in Handbook of the Biology of Aging (Academic Press, New York, 1996), pp. 121-149; P. J. Vojta and J. C. Barrett, Biochim. Biophys. Acta 1242, 29 (1996).
2. L. Hayflick and P. S. Moorhead, Exp. Cell Res. 25, 585 (1961); L. Hayflick, ibid. 37, 614 (1965); J. Campisi, G. Dimri, E. Hara, in Handbook of the Biology of Aging (Academic Press, New York, 1996), pp. 121-149; P. J. Vojta and J. C. Barrett, Biochim. Biophys. Acta 1242, 29 (1996).
3. L. Hayflick and P. S. Moorhead, Exp. Cell Res. 25, 585 (1961); L. Hayflick, ibid. 37, 614 (1965); J. Campisi, G. Dimri, E. Hara, in Handbook of the Biology of Aging (Academic Press, New York, 1996), pp. 121-149; P. J. Vojta and J. C. Barrett, Biochim. Biophys. Acta 1242, 29 (1996).
4. L. Hayflick and P. S. Moorhead, Exp. Cell Res. 25, 585 (1961); L. Hayflick, ibid. 37, 614 (1965); J. Campisi, G. Dimri, E. Hara, in Handbook of the Biology of Aging (Academic Press, New York, 1996), pp. 121-149; P. J. Vojta and J. C. Barrett, Biochim. Biophys. Acta 1242, 29 (1996).
5. C. B. Harley, A. B. Futcher, C. W. Greider, Nature 345, 458 (1990); H. Varizi and S. Benchimol, Exp. Gerontol. 31, 295 (1996).
6. C. B. Harley, A. B. Futcher, C. W. Greider, Nature 345, 458 (1990); H. Varizi and S. Benchimol, Exp. Gerontol. 31, 295 (1996).
7. K. S. Kulju and J. M. Lehman, Exp. Cell Res. 217, 336 (1995); J. A. Bond, M. Haughton, J. Blaydes, D. Wynford-Thomas, F. S. Wyllie, Oncogene 13, 2097 (1996).
8. K. S. Kulju and J. M. Lehman, Exp. Cell Res. 217, 336 (1995); J. A. Bond, M. Haughton, J. Blaydes, D. Wynford-Thomas, F. S. Wyllie, Oncogene 13, 2097 (1996).
9. N. J. Whitaker et al., Oncogene 11, 971 (1995).
10. A. Noda, Y. Ning, S. F. Venable, O. M. Pereira-Smith, J. R. Smith, Exp. Cell Res. 211, 90 (1994); H. Tahara, E. Sato, A. Noda, T. Ide, Oncogene 10, 835 (1995).
11. A. Noda, Y. Ning, S. F. Venable, O. M. Pereira-Smith, J. R. Smith, Exp. Cell Res. 211, 90 (1994); H. Tahara, E. Sato, A. Noda, T. Ide, Oncogene 10, 835 (1995).
12. E. M. Rogan et al., Mol. Cell. Biol. 15, 4745 (1995); D. A. Alcorta et al., Proc. Natl. Acad. Sci. U.S.A. 93, 13742 (1996); E. Hara et al., Mol. Cell. Biol. 16, 859 (1996); M. Serrano et al., Cell 85, 27 (1996); H. Wong and K. Riabowol, Exp. Gerontol. 31, 311 (1996).
13. E. M. Rogan et al., Mol. Cell. Biol. 15, 4745 (1995); D. A. Alcorta et al., Proc. Natl. Acad. Sci. U.S.A. 93, 13742 (1996); E. Hara et al., Mol. Cell. Biol. 16, 859 (1996); M. Serrano et al., Cell 85, 27 (1996); H. Wong and K. Riabowol, Exp. Gerontol. 31, 311 (1996).
14. E. M. Rogan et al., Mol. Cell. Biol. 15, 4745 (1995); D. A. Alcorta et al., Proc. Natl. Acad. Sci. U.S.A. 93, 13742 (1996); E. Hara et al., Mol. Cell. Biol. 16, 859 (1996); M. Serrano et al., Cell 85, 27 (1996); H. Wong and K. Riabowol, Exp. Gerontol. 31, 311 (1996).
15. E. M. Rogan et al., Mol. Cell. Biol. 15, 4745 (1995); D. A. Alcorta et al., Proc. Natl. Acad. Sci. U.S.A. 93, 13742 (1996); E. Hara et al., Mol. Cell. Biol. 16, 859 (1996); M. Serrano et al., Cell 85, 27 (1996); H. Wong and K. Riabowol, Exp. Gerontol. 31, 311 (1996).
16. E. M. Rogan et al., Mol. Cell. Biol. 15, 4745 (1995); D. A. Alcorta et al., Proc. Natl. Acad. Sci. U.S.A. 93, 13742 (1996); E. Hara et al., Mol. Cell. Biol. 16, 859 (1996); M. Serrano et al., Cell 85, 27 (1996); H. Wong and K. Riabowol, Exp. Gerontol. 31, 311 (1996).
17. O. Sugawara, M. Oshimura, M. Koi, L. A. Annab, J. C. Barrett, Science 247, 707 (1990); T. Ogata et al., Mol. Cell. Biol. 13, 6036 (1993).
18. O. Sugawara, M. Oshimura, M. Koi, L. A. Annab, J. C. Barrett, Science 247, 707 (1990); T. Ogata et al., Mol. Cell. Biol. 13, 6036 (1993).
19. S. Goldstein, Science 249, 1129 (1990).
20. D. A. Trott, A. P. Cuthbert, R. W. Overall, I. Russo, F. Newbold, Carcinogenesis 16, 193 (1995).
21. K. D. Hanson and J. M. Sedivy, Mol. Cell. Biol. 15, 45 (1995).
22. 2. Batches of FBS were tested for maximum single-cell cloning efficiency. FBS was added to medium immediately before use. Cultures were always passaged 1:4 at <80% confluence by brief treatment with 0.25% trypsin (without EDTA) and minimal pipetting. These conditions produce 30 to 50% single-cell cloning efficiency.
23. Lung fibroblasts were explanted from a first-trimester female embryo [A. E. Greene, in Tissue Culture Methods and Applications, P. F. Kruse and M. K. Patterson, Eds. (Academic Press, New York, 1973), pp. 69-72]. The primary culture was designated passage 0.
24. The neo-targeting vector had 5́ and 3́ flanks of 0.8 and 7.0 kbp, respectively. The hyg-targeting vector [T. Waldman, K. W. Kinzler, B. Vogelstein, Cancer Res. 55, 5187 (1995)] had 5́ and 3́ flanks of 4.6 and 4.0 kbp, respectively. Neither vector contained the p21 promoter or negatively selectable markers. Electroporation conditions; 0.8 ml of F10 medium (without serum), 0.4-cm cuvette, 20°C, 260 V, 975 μF, Bio-Rad Gene Pulser II apparatus. These conditions produce 6% transient electroporation efficiency.
25. HE and HO indicate heterozygous and homozygous derivatives, respectively. Nontargeted siblings are identified by clone number only. LF1 and HO7.2-1 cells tested negative for mycoplasma, human immunodeficiency virus, and HPV, and their karyotypes were normal.
26. J. P. Brown and J. M. Sedivy, unpublished observations.
27. Each round of targeting was performed with a different nonisogenic vector [H. te Riele, E. R. Maandag, A. Berns, Proc. Natl. Acad. Sci. U.S.A. 89, 5128 (1992)]. We have also targeted the p53 gene with efficiencies of 5. 6, and 33% in three separate experiments with two different HDF cell strains and isogenic as well as nonisogenic vectors (15). These results indicate that isogenic vectors are not necessary for gene targeting in human cells and that our targeting strategy is neither locus-nor cell strain-specific.
28. Cultures were considered senescent when 1 PD took longer than 2 weeks. Senescent cultures were >95% β-galactosidase-positive [G. P. Dimri et al., Proc. Natl. Acad. Sci. U.S.A. 92, 9363 (1995)] and could be maintained for over 2 months without a significant decrease in cell number (15).
29. Passage number after gene targeting was arbitrarily set to 0 for each cell strain when the culture was first expanded into a 10-cm culture dish.
30. Low-level mitotic activity coexisted with cell death; cells of variable size, irregular shape, and a significant number of large multinucleated cells were observed; cultures gradually declined over 6 to 8 weeks (15).
31. C. B. Harley et al., Cold Spring Harbor Symp. Quant. Biol. 59, 307 (1994).
32. J. W. Shay, W. E. Wright, H. Werbin, Biochim. Biophys. Acta 1072, 1 (1991); V. J. Cristofalo and R. J. Pignolo, Physiol. Rev. 73, 617 (1993).
33. J. W. Shay, W. E. Wright, H. Werbin, Biochim. Biophys. Acta 1072, 1 (1991); V. J. Cristofalo and R. J. Pignolo, Physiol. Rev. 73, 617 (1993).
34. C. M. Counter et al., EMBO J. 11, 1921 (1992).
35. Telomerase activity was assayed by the telomere repeat amplification protocol [N. W. Kim, et al., Science 266, 2011 (1994)].
36. W. Wei and J. M. Sedivy, unpublished observations.
37. C. Deng, P. Zhang, J. W. Harper, S. J. Elledge, P. Leder, Cell 82, 675 (1995).
38. T. Waldman, C. Lengauer, K. W. Kinzler, B. Vogelstein, Nature 381, 713 (1996).
39. Apoptotic cell death was demonstrated by flow cytometry (75), in situ DNA end labeling [Y. Gavrieli, Y. Sherman, A. A. Ben-Sasson, J. Cell Biol. 119, 493 (1992)], and nucleosomal laddering (24).
40. L. R. Livingstone et al., Cell 70, 923 (1992).
41. We thank R. Halaban for establishing cell strains, H. Ozer and J. McCormick for advice on HDF culture, B. Vogelstein for the hyg p21 vector, and H.-F. Mark for karyotype analysis. Supported by grants from the Yale Skin Disease Research Center and the American Anti-vivisection Society (J.P.B.) and by NIH grant GM41690 (J.M.S).